rVSV-ZEBOV
E85063
Ebola vaccine
live attenuated vaccine
recombinant viral vector vaccine
vesicular stomatitis virus-based vaccine
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
Aliases (2)
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola vaccine
→
live attenuated vaccine → recombinant viral vector vaccine → vesicular stomatitis virus-based vaccine → |
| administeredTo |
adults
→
|
| alsoKnownAs |
Ervebo
→
V920 → rVSVΔG-ZEBOV-GP → |
| category |
WHO-recommended Ebola vaccine
→
|
| contraindication |
use in certain immunocompromised individuals may be restricted
→
use in pregnancy may be restricted → |
| design |
recombinant VSV with Ebola virus glycoprotein gene replacing VSV glycoprotein gene
→
|
| developedFor |
protection against Ebola virus infection in humans
→
|
| dosageForm |
injectable suspension
→
|
| efficacyDemonstratedIn |
ring vaccination trial in Guinea
→
|
| expressesAntigen |
Ebola virus glycoprotein
→
|
| geographicUse |
Democratic Republic of the Congo
→
Guinea NERFINISHED → Liberia → Sierra Leone → |
| immuneResponseType |
cell-mediated immune response
→
humoral immune response → |
| indicatedFor |
individuals at risk of exposure to Ebola virus
→
|
| licensedTo |
NewLink Genetics
→
|
| marketingAuthorizationHolder |
Merck & Co.
→
|
| mechanismOfAction |
induces immune response against Ebola virus glycoprotein
→
|
| originalDeveloper |
Public Health Agency of Canada
→
|
| publicHealthUse |
ring vaccination strategy around confirmed Ebola cases
→
|
| regimen |
single-dose vaccination
→
|
| regulatoryStatus |
received WHO prequalification
→
received regulatory approvals in multiple countries → |
| riskGroupUse |
healthcare workers at risk of Ebola exposure
→
laboratory personnel handling Ebola virus → |
| routeOfAdministration |
intramuscular injection
→
|
| safetyProfile |
commonly causes transient injection-site and systemic reactions
→
|
| sponsorInKeyTrials |
Guinean Ministry of Health
→
Norwegian Institute of Public Health → World Health Organization → |
| storageRequirement |
requires cold-chain storage
→
|
| subsequentlyDevelopedBy |
Merck & Co.
→
|
| targetDisease |
Ebola virus disease
→
|
| targetPathogen |
Zaire ebolavirus
→
|
| targetStrain |
Ebola virus Zaire strain
→
|
| trialDesign |
cluster-randomized ring vaccination trial
→
|
| trialPhase |
Phase III clinical trial
→
|
| trialPopulation |
contacts and contacts-of-contacts of Ebola cases
→
|
| usedDuringOutbreak |
2014–2016 West African Ebola outbreak
→
2018–2020 Ebola outbreaks in the Democratic Republic of the Congo → |
| vaccineType |
replication-competent viral vector vaccine
→
|
| vaccineVector |
vesicular stomatitis virus
→
|
Referenced by (5)
| Subject (surface form when different) | Predicate |
|---|---|
|
2014–2016 West Africa Ebola outbreak
→
2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo ("rVSV-ZEBOV Ebola vaccine") → |
vaccineUsed |
|
rVSV-ZEBOV
("rVSVΔG-ZEBOV-GP")
→
|
alsoKnownAs |
|
Zaire ebolavirus
→
|
approvedVaccine |
|
Ebola virus disease
→
|
vaccine |